This will be a somewhat shorter post than yesterday's: not because its material is any less important, but simply because somewhat less demands to be said about the two cases I feature today than about yesterday's unholy trinity. Two decisions this year demanded that the high court take some role in shaping the post- Dobbs landscape of abortion jurisprudence. They may be considered opposite ends of a spectrum. One of these involved FDA approvals of early-term abortion medications: the second questioned whether the federal government has mandated life-saving abortions in hospital emergency rooms in a manner that can pre-empt state law. First then, last month the Supreme Court dismissed FDA v. Alliance for Hippocratic Medicine , a lawsuit in which the named Alliance sought to restrict access to the pill mifepristone. Non-surgical abortions are typically conducted with a two-pill regimen: mifepristone followed by misoprostol. This seems to be the most effective (a...